Moffitt | Strategic Alliance Partners

Latest from Moffitt


Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?

September 30, 2021

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial Cancer

September 30, 2021

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Checkpoint Inhibitors Demonstrate Broad Reach in GU Cancers

September 28, 2021

Rohit Jain, MD, MPH, discusses the nuances of treatment selection for patients with platinum-eligible vs -ineligible metastatic urothelial carcinoma, the current state of immunotherapy in this disease, and factors to consider during the decision-making process in RCC and mCRPC.